Mainz Biomed (NASDAQ:MYNZ) Short Interest Update

Mainz Biomed (NASDAQ:MYNZ) was the target of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 79,700 shares, a decrease of 21.6% from the February 13th total of 101,700 shares. Based on an average daily trading volume, of 208,300 shares, the short-interest ratio is presently 0.4 days. Currently, 3.8% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of brokerages have recently commented on MYNZ. HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th. Maxim Group began coverage on shares of Mainz Biomed in a research report on Friday, February 14th. They issued a “buy” rating and a $14.00 target price for the company.

Institutional Investors Weigh In On Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC acquired a new position in shares of Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned about 0.92% of Mainz Biomed at the end of the most recent quarter.

Mainz Biomed Trading Down 10.2 %

Mainz Biomed stock traded down $0.47 during midday trading on Tuesday, hitting $4.16. 131,233 shares of the stock were exchanged, compared to its average volume of 90,540. Mainz Biomed has a fifty-two week low of $3.65 and a fifty-two week high of $45.20. The stock has a market capitalization of $8.32 million, a price-to-earnings ratio of -0.06 and a beta of 0.33. The stock’s 50-day simple moving average is $5.46 and its 200 day simple moving average is $7.93.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.